Objective: There are significant individual differences in the extent to which mood and cognition change as a function of reproductive stage, menstrual phase, postpartum, and hormone therapy use. This review explores the extent to which variations or polymorphisms in the estrogen receptor > gene (ESR1) predict cognitive and mood outcomes.
BIOLOGICAL PLAUSIBILITY THAT ESTROGEN
IMPACTS COGNITION AND MOOD Estrogen facilitates synaptogenesis, induces growth factor production, protects against oxidative stress, and regulates neurotransmission (eg, serotonin, norepinephrine, and acetylcholine) in brain systems associated with cognition and mood. 1<4 The regulatory effects of estrogen on choline acetyltransferase and acetylcholinesterase are particularly relevant to cognition given the key role of cholinergic transmission in learning, memory, and Alzheimer disease (AD). 5<7 Clinical studies demonstrate the effects of estrogen supplementation and withdrawal on mood and cognitive outcomes, but the magnitude and direction of these effects seem to be influenced by the dose, timing, and formulation of estrogen treatment. 8, 9 There is notable variability in clinical response to hormone treatments, including hormone therapy for menopausal symptoms 10 and tamoxifen treatment for breast cancer. 11, 12 Moreover, there are significant individual differences in the extent to which cognitive function and mood change as a function of reproductive stage 13, 14 and a high degree of interindividual and intra-individual variability in the risk and severity of postpartum depression 15 and premenstrual dysphoric disorder. 16, 17 This review explores the extent to which individual differences in genes associated with estrogen signaling predict cognitive and mood outcomes.
Estrogen activity in the brain is mediated through activation of intracellular, transmembrane, and membrane-bound estrogen receptors (ERs) along with nongenomic mechanisms. In addition to the transmembrane estrogen G proteinYcoupled receptor GPR30, there are two subtypes of ERs, ER-> and ER-A. 18 The ER-> and ER-A receptor subtypes are members of the superfamily of nuclear receptors that regulate transcription in target genes containing estrogen response binding elements. The ER receptor subtypes are encoded by two distinct genes. The ER-> gene (ESR1) is located on chromosome 6q25.1, and the ER-A (ESR2) gene is located on chromosome 14q22-24. 19 Both the ER-> and ER-A receptor subtypes are located in brain regions associated with cognitive function and emotion. The ER-> receptor is predominantly expressed in the hypothalamus and amygdala, areas involved in autonomic function, emotional regulation, and associative and emotional memory. The ER-A receptor is predominantly expressed in the hippocampal formation and entorhinal cortex, brain areas involved in declarative memory. 18 The high level of ER-A expression in the hippocampus suggests a role for ER-A in cognitive function; however, mental health studies have focused mainly on the ER-> gene.
Studies in large populations have reported independent relationships between ESR2 polymorphisms and risk for depression in adolescents 20 and for AD. 21, 22 These associations must be considered preliminary because there are few ESR2 studies. Moreover, subsequent studies have failed to replicate the findings associating ESR2 polymorphisms and mental health outcomes. 23<25 GPR30 polymorphisms have been studied in relation to breast cancer, but not mental health outcomes. 26 For these reasons, the present review focuses on polymorphisms in the ESR1 gene and their role in mental health.
GENETIC VARIATION IN ER-> AND
WOMEN'S HEALTH Several single nucleotide polymorphisms (SNPs) and variable-number tandem repeat polymorphisms have been identified in ESR1. 27 Among these identified polymorphisms, only a few have been extensively studied in relation to health outcomes. One well-studied polymorphism is a TA-variable number of tandem repeats in the promoter region that may impact tissue-specific gene expression. 28 This TA-repeat polymorphism is in strong linkage disequilibrium with two of the most widely studied SNPs in the ESR1 gene, PvuII (rs9340799) and Xbal (rs223493), which are located in the first intron of ESR1 and are in strong linkage disequilibrium with each other. 29 See Figure 1 for a schematic diagram of the genomic organization of the ESR1 gene. In linkage disequilibrium, some combinations of alleles occur more frequently in a population than would be expected from random assortment. Therefore, because PvuII and Xbal are in linkage disequilibrium, one can predict the allele at one SNP given the allele at the other SNP with a high level of confidence. The T and C alleles of the PvuII SNP are commonly referred to as the p and P allele, respectively. The A and G alleles of Xbal are commonly referred to as the x and X allele, respectively. The X and P are the variant alleles that lack the respective XbaI and PvuII restriction enzyme recognition site. Currently, there is no definitive evidence concerning the functionality of these SNPs or the biological pathways they affect; however, recent findings support the hypothesis that these SNPs impact estrogen activity by influencing transcription of the ESR1 gene via altered transcription factor binding. 30, 31 It is possible that the Xbal and PvuII SNPs as well as the TA-repeat do not affect estrogen signaling directly but may be in linkage disequilibrium with another functional variant in the ESR1 gene.
The ESR1 polymorphisms seem to be markers for important clinical outcomes in women, such as bone mineral density 29,32<34 and cardiovascular health. 30,35<37 The polymorphisms have been implicated in estrogen-related diseases including breast cancer, 38<40 osteoporosis, 29, 33, 41, 42 endometriosis, 43<46 and familiar premature ovarian dysfunction. 47 These associations are controversial because of inconsistent findings across studies. 48, 49 It is difficult to determine which alleles are associated with physiological states that are consistent with optimal estrogen signaling. Most studies indicate that the p and x alleles seem to confer risk for breast cancer and osteoporosis yet reduce risk for endometriosis. The associations between the TA-repeat polymorphism and health outcomes seem to be more consistent. Typically, a lower number of repeats are associated with lower bone mineral density and a higher incidence of osteoporotic fractures. 29, 33, 42 In addition, a lower number of repeats confer a greater risk of endometriosis 43<45 and premature ovarian dysfunction. 47 ESR1 associations are frequently found to be ethnicity/race specific. For example, a recent meta-analysis concluded that most studies in Asian populations found an association between the PP and/or xx genotypes with increased risk of osteoporosis, whereas the pp and/or xx genotypes were associated with increased risk of osteoporosis in white populations. 50 A genetic haplotype is a combination of alleles from different loci along a chromosome that tend to be inherited together. It is reasoned that the specificity of ESR1 relationships by race or ethnicity may reflect the twofold higher prevalence of the Risk of AD was associated with five SNPs located between intron 3 and intron 7 (rs1514348, P = 0.027; rs2347867, P = 0.001; rs6557171, P = 0.035; rs9397456, P = 0.024; rs1801132, P = 0.019), and age of AD onset was associated with two SNPs located on exon 2 (rs2077647, P = 0.036) and intron 2 (rs3853248, P = 0.011 Px haplotype in Asian populations relative to white populations. 42 Two recent molecular studies have supported a relationship between the p allele and risk of osteoporosis. A functional binding site for the transcription factor B-myb was found to be absent with the p allele of PvuII, which, in turn, may reduce ESR1 transcription rates or produce a functionally different ESR1 isoform. 31, 35 Higher plasma estradiol levels were found in postmenopausal women carrying the XP haplotype 31 ; however, other studies found no association between serum estradiol levels and ESR1 polymorphisms. 51, 52 Taken together, the current literature suggests that ESR1 transcription activity and/or gene regulation are affected by ESR1 polymorphisms, but the exact biological mechanism remains to be determined.
There is a striking similarity between the regional distribution of ERs and brain areas affected by AD neuropathology, including the hippocampus, entorhinal cortex, and basal forebrain. 1, 53 Decreased levels of ER-> have been found in hippocampal neurons in the brains of AD patients. 54 Mice lacking ER-> (ie, ESR1 knockout mice) show impaired performance on cognitive tasks dependent on the hippocampus, a brain region that is critical for memory formation. 55, 56 This cognitive impairment is reversed with estradiol administration 56 or with lentiviral delivery of the ESR1 gene to the hippocampus. 57 Such evidence that ER-> plays a role in cognitive function has fueled a series of studies examining the relationship between ESR1 genotype and cognitive function. Fewer studies have examined the association between ESR1 genotype and mood outcomes. The present review aims to facilitate future research in relationships between genetic variation in the ESR1 gene and mental health by summarizing the current findings.
This review focuses primarily on findings pertaining to the most widely studied polymorphisms, PvuII, Xbal, and the TA-repeat; however, findings regarding other ESR1 polymorphisms are reported when they were investigated in conjunction with PvuII, Xbal, and/or the TA-repeat. In addition, we offer potential explanations for discrepant results, discuss potential clinical implications, and suggest areas of focus for future research and methodology that may be advantageous in further characterizing relationships between ER genes and mental health.
METHODS
For this systematic review of ESR1 polymorphisms and mental health, we focused on studies relating ESR1 polymorphisms to cognitive and mood outcomes. We carried out a literature search from 1995 to November 2009 through PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), Embase (http://www.embase.com/), and PsychINFO (http://www.apa. org/pubs/databases/psycinfo/index.aspx). We also consulted previous reviews. We selected only publications in the English language and used combinations of the following key words: estrogen receptor polymorphisms, ESR1 polymorphisms, estrogen receptor alpha, rs2234693, rs9340799, cognition, cognitive function, memory, mood, depression, and The studies included were heterogeneous in study design, sample size, and the statistical covariance of factors other than genetics that influence estrogen signaling (eg, reproductive stage, age, use of hormone therapy, or psychotropic medication). This heterogeneity among ESR1 studies precluded conducting a formal meta-analysis. We therefore summarized findings by study design in a narrative review. Details of the studies investigating ESR1 polymorphisms and cognitive function are summarized in Tables 1 and 2 . Details of studies investigating ESR1 polymorphisms and mood outcomes are summarized in Table 3 . Figures 2 and 3 present a basic summary of the main findings regarding ESR1 alleleYspecific relationships with cognitive and mood outcomes.
ESR1 POLYMORPHISMS AND COGNITION Approximately 50% of the genetic risk factors for sporadic AD are yet to be discovered. 58 Early evidence indicating a relationship between the ESR1 gene and cognition came primarily from case-control studies. More recently, prospective cohort studies have investigated relationships between ESR1 and cognitive outcomes longitudinally. Most case-control studies indicate a potential relationship between the X and P alleles of XbaI and PvuII and increased risk of cognitive impairment. However, three prospective studies and studies relating ER genes to cognitive function in healthy older adults provide different results. The following sections summarize these results by study design, focusing first on casecontrol studies and then on prospective studies. Table 1 summarizes the case-control studies to date examining the link between ESR1 polymorphisms and cognitive outcomes. Figure 2A shows that 78% of the case-control studies reported an association between ESR1 polymorphisms and odds of cognitive impairment and that 73% of those positive studies demonstrate a protective effect of the x and p alleles of the Xbal and PvuII SNPs, respectively, against cognitive impairment. We describe these case-control studies in greater detail in the BCase Control Studies[ section of BESR1 Polymorphisms and Cognition.[ We also review evidence indicating that the risk of dementia associated with X and P alleles is greater in individuals with the APOE e4 allele, a known risk factor for AD.
Case-control studies
The earliest case-control study involved a Japanese sample of sporadic AD patients and healthy older controls. 59 The frequencies of the X and P alleles were significantly higher in the AD patients versus the controls. 59 In a sample of postmenopausal Danish women, neither the X nor the P allele was associated with increased odds of cognitive impairment as assessed by the six-item Orientation-Memory-Concentration test. 60 In a secondary, atypical analysis, the X allele was associated with an increased odds of cognitive impairment (P = 0.054) after adjusting for Bexecutive cognitive ability. [ 60 In an Italian sample of AD patients and older controls, findings contrary to previous case-control studies were reported: the xx genotype was associated with increased odds of developing AD. 61 This effect was driven by women and by patients with late-onset AD. No relationship was found with the PvuII SNP. 61 In a mostly female sample of Chinese AD patients and older controls, 16 ESR1 SNPS were examined and no significant associations were found with the Xbal or PvuII SNP. 62 However, the odds of developing AD was associated with five SNPs located between intron 3 and intron 7, and age of AD onset was associated with two SNPs located on exon 2 and intron 2. In a subanalysis restricted to women, the five ESR1 SNPs were significantly associated with increased odds of AD. 62 Other case-control studies found no association between ESR1 polymorphisms and odds of developing AD. 63<65 A recent meta-analysis described evidence from eight case-control studies examining whether PvuII and Xbal SNPs increased the odds of developing AD (n = 8,288) or other forms of dementia (n = 11,036). 66 A small but significant association between each SNP and odds of developing AD was found (X carriers: odds ratio [OR], 1.2; 95% CI, 1.0-1.4; P = 0.02; P carriers: OR, 1.2; 95% CI, 1.0-1.4; P = 0.01). In ethnicity-specific analyses, these associations were significant in Asian (X carriers: OR, 1.5; 95% CI, 1.1-2.0; P = 0.004; P carriers: OR, 1.5; 95% CI, 1.1-2.0; P = 0.01) but not European (Xbal: OR, 1.1; 95% CI, 0.9-1.3; P = 0.37; PvuII: OR, 1.1; 95% CI, 0.9-1.3; P = 0.27) populations. Conversely, no ESR1 SNPs were associated with non-AD forms of dementia. 66 ESR1 polymorphisms did not relate to odds of all-cause dementia, 66,67 vascular dementia, 68 alcohol-associated dementia, 68 or Parkinson disease with dementia. 69 However, the studies may not have been adequately powered to detect these relationships considering that the non-AD dementia groups were often small or smaller compared with the AD group. On the contrary, Isoe-Wada et al 70 reported that the prevalence of the P allele was significantly higher in PD patients with dementia (63%) and AD patients (49%) compared with controls (36%). The prevalence of the X allele was significantly higher in AD patients (29%) compared with controls (17%). 70 There is some evidence that the odds of developing AD with a particular ESR1 may be greater in individuals with the APOE e4 allele, a well-established risk factor for AD. 71<73 Estrogen mediates the regulation of APOE synthesis 74 and promotes synaptogenesis through an APOE-dependent mechanism. 75 Three studies report no interactive effects of APOE and ESR1 on cognitive function. 23, 52, 61 Three other studies found a similar significant pattern of interaction. The first study involved a Japanese sample of older controls and patients with vascular dementia, alcohol-associated dementia, early-and late-onset AD, and familial AD. 68 The frequencies of the P and X alleles were significantly higher in late-onset AD patients with one or more e4 alleles (P, 51%; X, 30%) compared with healthy older controls (P, 38%; X, 20%). 68 In an Italian study of sporadic AD patients and older controls, the PP and XX genotypes were associated with increased risk for AD in men only but conferred a substantial increased risk of AD to male and female participants who carried an APOE e4 allele (OR, 13.3; 95% CI, 1.7-103.6). 76 A subsequent Italian study reported a higher prevalence of both the PP and XX genotypes and the combined PPXX genotype in sporadic, late-onset AD patients (PPXX, 22%) compared with controls (PPXX, 9%). 77 Notably, the cumulative effect of the PPXX genotype and e4 homozygosity conferred a sevenfold increased risk of AD compared with e4-negative participants. 77 A Swedish study reported the opposite pattern of interactions in a clinic-based sample of familial AD patients and controls as well as a community-based sample of female patients with familial AD or sporadic AD and older controls. 78 In both the clinic-and community-based samples, the combination of the APOE e4 allele and the ESR1 xx or pp genotype was associated with increased risk of familial AD in women, particularly among early-versus late-onset AD patients. 78 Together, these findings provide some evidence that ESR1 and APOE polymorphisms may interact to influence risk of cognitive decline, but the pattern of those effects varies. Table 2 summarizes the prospective cohort studies to date examining the link between ESR1 polymorphisms and cognitive outcomes. As illustrated in Figure 2B , 75% of cohort studies reported significant associations between ESR1 polymorphisms and cognitive decline. In contrast to the casecontrol studies, 100% of those positive studies showed a protective effect of the X and P alleles of Xbal and PvuII against cognitive decline.
Prospective cohort studies
Two recent prospective studies by the same lead investigator suggest that the p and x alleles are associated with an increased risk of cognitive impairment as measured by the modified Mini-Mental Status Examination (MMSE). 51, 52 The first study was a prospective cohort study with a 6to 8-year follow-up in a sample of predominantly white, older women. 51 Compared with women with the XX or PP genotype, women with a p or x allele experienced greater cognitive decline over time. In addition, p and x alleles were more frequent in women who developed cognitive impairment (p, 62%; x, 70%) compared with those who did not (p, 56%; x, 64%). Most compelling was the finding that women with a pp or xx genotype had a threefold greater risk of AD or dementia compared with women with a PP or XX genotype. 51 These findings were confirmed in another prospective cohort study of nondemented older men and women. 52 The p and x alleles increased the risk for cognitive impairment in women. In men, cognitive impairment was associated with the ESR1 rs728524 SNP. Levels of circulating estradiol did not relate to any ESR1 SNPs, and the results were attenuated somewhat after controlling for race. 52 Most studies examining 
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Health Across the Nation (SWAN). 23 X and P alleles were associated with better performance on only one cognitive domain, verbal memory, as assessed by the East Boston Memory Test. The association with verbal memory was dependent on ethnicity such that white and African American women who were homozygous for the X allele performed better on the East Boston Memory Test compared with women without this genotype. Among white women, those who were homozygous for the P allele performed better than did those without this genotype on the delay memory trial. There was no relationship between ESR1 polymorphisms and any other cognitive measure, including working memory (Digit Span Backwards) and perceptual speed (Symbol Digit Modalities). 23 A prospective cohort study in older, white adults found no relationship between ESR1 SNPs and MMSE score or dementia risk. 67 In a subset of individuals with structural brain scans, women with the p or x allele or haplotypes of the p and x allele had smaller hippocampal and amygdalar volumes compared with women with the P or X allele, and the loss of brain volume increased as the number of risk alleles increased. 67 
Overall summary of ESR1 polymorphisms and cognitive function
Whereas most case-controlled studies found an association between cognitive decline and the X and P alleles, 60, 68, 77 prospective cohort studies 23, 51, 52 generally found an association between cognitive decline and the x and p alleles. Yaffe et al 51 suggested that differences in ethnic background across samples, specifically the greater representation of Japanese individuals in the case-control studies, may account for this difference and recommended further research within different ethnic groups. This argument is supported by the metaanalysis showing a link between the x and p alleles and AD only in Asian samples. 66 Ethnicity-specific analyses are also important because of variability in the degree of linkage disequilibrium between ESR1 polymorphisms across race or ethnic groups. 42, 50 Variations in ESR1 alleleYspecific associations may also be due to the numerous interactions between environmental and genetic risk factors. For example, a casecontrol study 25 showed a significant interaction between an SNP on exon 8 of the ESR2 gene and both the PvuII and Xbal SNPs of ESR1. Also, as noted earlier, the ESR1 and APOE genotypes interact to influence the risk of dementia. 68,76<78 Overall, these studies provide evidence that genetic variation in the ESR1 gene is associated with memory function at midlife and risk of dementia. This evidence is consistent with predictions based upon the presence of ESR1 mRNA in the amygdala-hippocampal area and entorhinal cortex. 79 Although a few studies reported relationships in men, 52, 76 more studies reported relationships in exclusively female samples 23, 51, 60, 78 or relationships that were driven by women in a mixed-sex sample. 52, 61, 62 Results from a meta-analysis 66 indicate that the relationship between ESR1 polymorphisms and cognitive impairment may be specific to AD rather than all-cause dementia. Consistent with this clinical effect, three studies suggest that ESR1 polymorphisms may impact disease expression. First, a postmortem study found a trend for an association between the P allele and greater AD pathology (ie, neurofibrillary tangles) in the brains of 551 Japanese individuals. 80 Second, Corbo et al 76 reported an association between the PP and XX genotypes and lower MMSE values in women with AD. Third, age at AD onset has been associated with two ESR1 SNPs on intron 2 and exon 2. 62 ESR1 POLYMORPHISMS AND MOOD Twin and family-based studies indicate a significant genetic component to major depressive disorder (MDD), and heritability is highest with severe, recurrent, and early-onset forms of the disease. 81<84 Epidemiological studies have consistently demonstrated a higher prevalence for MDD in women compared with men. 85, 86 This sex disparity emerges at puberty. 87, 88 Multiple lines of evidence have implicated estrogen signaling as contributing to this sex difference. 89<91 Women show an increased risk of MDD during the perimenopausal period, a reproductive stage characterized by fluctuations in estradiol levels. 92 Estrogen modulates serotonergic and norepinephrinergic function, 93 both of which are central to affective processing. Lastly, of the two ER subtypes, ER-> is more predominantly expressed in brain areas that mediate affective and motivational processing, including the amygdala and hypothalamus. Furthermore, as noted earlier, smaller amygdala and hippocampal volumes were associated with the p and x alleles of the PvuII and Xbal SNPs in older, healthy women. 67 Table 3 summarizes the studies to date examining the link between ESR1 polymorphisms and mood outcomes. Figure 3 illustrates that 60% of studies examining ESR1 polymorphisms in relation to anxiety or depressive symptoms found significant associations. Each of these positive studies reported that the X and/or P alleles of Xbal and PvuII or longer TA-repeat alleles were risk factors for anxiety or depression.
A population-based cohort study of white individuals 55 years or older found that the Xbal and PvuII polymorphisms related to anxiety in women but not depressive symptoms or Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition depressive disorder in women or men. 94 The XP haplotype was associated with an increased risk for anxiety symptoms in women in a dose-dependent manner. 94 A Chinese study involving patients with MDD and healthy controls reported a threefold higher risk of MDD in women who were homozygous for the P allele of the PvuII variant compared with women with Pp or pp genotypes. 95 No such relationships were evident in men. In a sample of adult men treated for substance abuse, the ESR1 TA-repeat polymorphism was significantly associated with anxiety symptoms. 96 There is variable evidence of a relationship between ESR1 polymorphisms and depression or anxiety in women-only samples. There was no evidence of an association between ESR1 SNPs and depressive symptoms as measured by the Center for Epidemiological Studies Depression Scale in a multiracial/ multiethnic sample of women participating in SWAN. 24 Importantly, women taking antidepressant medication were excluded from these analyses, which may represent a form of selection bias if, compared with the study population, there is a higher prevalence of the genetic risk factor among the women excluded because of use of antidepressants. A recent study examined the relationship between premenstrual dysphoric disorder and genetic variation in the ESR1 gene, the ESR2 gene, and the catechol-O-methyltransferase (COMT) gene, a gene involved in estrogen metabolism. 97 Four SNPs in intron 4 of ESR1 showed significantly different allele distributions and genotype distributions between affected women and controls. 97 Additional studies have investigated ESR1 polymorphisms and prevalence of a mood disorder and personality traits reflecting dysphoric mood states. PvuII and Xbal variants did not predict odds of developing a childhood-onset mood disorder in a large family-based sample of affected children and their immediate family members. 98 In women, however, there was an association between childhood-onset mood disorders and a haplotype of three other ESR1 SNPs in strong linkage disequilibrium (rs746432, rs2077647, and rs532010). 98 No relationship between the PvuII variant and MDD or bipolar disorder was found in a Japanese study. 99 No relationship between ESR1 polymorphisms and suicidal behaviors was found in a German population. 100 
Summary of ESR1 polymorphisms and mood
The paucity of studies examining ESR1 genotype and mood outcomes necessitates caution when interpreting the results; however, the findings offer preliminary evidence that the ESR1 gene may play a role in susceptibility to mood disorders, particularly for women. It becomes especially important to investigate the influence of ER polymorphisms in clinical populations that are prone to mood disorders, such as patients with HIV, dementia, chronic inflammatory conditions, and cancers. Such investigations will bring us closer to the possibility of using genetic markers to identify patients who are at increased risk for mood disorders.
DISCUSSION
There seems to be a strong relationship between ESR1 polymorphisms and cognitive outcomes. Initial studies investigating ESR1 variants and mood disorders suggest a similar trend. As with the literature on osteoporotic fracture risk, the literature on cognitive risk factors shows some inconsistencies concerning which particular ESR1 polymorphisms conferred risk and the directionality of allele-specific effects. Most, but not all, of the case-control studies indicate that the X and P alleles of XbaI and PvuII confer the risk for cognitive impairment. Conversely, three prospective cohort studies in a healthy, older adult population suggest that the x and p alleles confer the risk. Despite these inconsistencies, two findings seem to be reliable: first, that the risk for cognitive impairment is found primarily in women, and second, that the risk is for AD rather than for other causes of de-mentia. Lastly, many of the studies of ESR1 polymorphisms and mental health outcomes found that relationships were evident in an exclusively female sample or that women drove such effects in mixed-sex samples. Future studies should acquire sufficiently large sample sizes to permit sex-stratified analyses. Additional insights into the discordant results will come from future studies that include haplotype analyses and analyses by ethnic/racial populations.
Investigations involving ESR1 haplotypes and epistatic relationships seem to produce more reliable and robust results compared with investigations involving single SNP analyses. Most studies using haplotype analyses found stronger gene associations when considering combinations of ESR1 PvuII and Xbal polymorphism genotypes and combinations of ESR1 genotypes with APOE polymorphisms. ESR1 haplotypes and epistatic relationships may relate more strongly to functional outcomes than do single SNP analyses because they provide more information on other genetic variants that influence estrogen activity through different mechanisms.
Many studies report ethnicity-or race-specific gene associations, which underscore the importance of considering genetic background and population stratification. There is minor racial and ethnic variation in distributions of the PvuII and Xbal genotypes 101 ; however, the degree of linkage disequilibrium between ESR1 polymorphisms may vary between ethnic/race groups. There is a twofold higher prevalence of the Px haplotype in Asian populations relative to white populations. 42 In addition, the number of TA-repeats differs by ethnicity, with estimated major peaks at 14 repeats in European populations and 15 repeats in Asian populations. 50 Moreover, studies indicate that there are ethnic disparities in the presentation and severity of menopause symptoms, particularly psychosomatic symptoms and hot flashes, 13, 102, 103 suggesting that ethnicity/race may be a factor influencing one's sensitivity to sex hormone fluctuations. The variations in menopausal symptoms and the distribution of ESR1 genotypes by ethnicity/race underscore the need to control for population stratification or heterogeneity in future studies. Two major differences between the case-control and cohort studies allow for further speculation into the disparate results. Across all studies, the average age of participants in the cohort studies was somewhat lower than in the casecontrol studies. In addition, most case-control studies involved AD outcomes whereas cohort studies involved cognitive decline outcomes. The case-control findings might therefore represent the impact of the SNPs on the more severe form of cognitive impairment in an older population, whereas the cohort findings represent the impact of the SNPs on generalized cognitive aging in a midlife to older population. This pattern might then suggest that the optimal level of estrogen signaling is one level in an intact brain (or earlier in life) and a different level in a diseased brain (or later in life). Such a conclusion would be similar to the Bhealthy cell bias[ of estrogen, 104 which proposes that estrogen can exert neuroprotective effects only in a healthy brain that is free of neurodegeneration. 
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Although the literature on ESR1 and mood is sparse, there is preliminary evidence that mood varies with ESR1 genotype. One study found an association between anxiety symptoms and the XP haplotype in women, 94 whereas another study demonstrated an increased risk of MDD diagnosis in women homozygous for the P allele. 95 Other ESR1 SNPs have been associated with childhood-onset mood disorders 98 and premenstrual dysphoric disorder. 97 Among men treated for substance abuse, the TA-repeat polymorphism was associated with anxiety symptoms. 96 To date, no studies have examined the interaction between ER polymorphisms and serotonin signaling genes such as the serotonin transporter gene (5HTT). Estrogen regulates serotonergic synthesis, degradation, and neuron firing rates in the raphe nuclei. 4 Some studies have found that clinical response to selective serotonin reuptake inhibitors is negatively affected by hypoestrogenic states such as menopause. 105<107 A few studies showed improved clinical response to selective serotonin reuptake inhibitors in postmenopausal women when the medication regimen was supplemented with hormone therapy compared with placebo. 107<109 Given that neurocognitive dysfunction is typically recognized as a core feature of MDD, it is worthwhile to consider the potential interactions among ESR1 polymorphisms, mood outcomes, and cognitive impairment. A history of depressive symptoms is common in about 20% to 30% of individuals with dementia. 110 Hippocampal volume loss, a characteristic of AD, is also reliably observed in patients with MDD. 111<114 Hyperactivity of the hypothalamic-pituitary-adrenal axis affects hippocampal and amygdala volume and is evident in both depression and AD. 115 Despite these potential links, there is no strong evidence to date that ESR1 effects on cognitive impairment are related to effects on mood. For example, the x and p alleles were risk factors for memory decline in white and African American postmenopausal women enrolled in SWAN 23 but were not associated with an increased risk of increased depression scores. 24 Across non-Asian populations, x and p are risk factors for cognitive decline but are associated with decreased risk of depression.
There are many more studies linking mental health outcomes to ESR1 SNPs than to ESR2 SNPs. This discrepancy may suggest that the ER-> receptor is a stronger determinant of mental health outcomes or that there is a publication bias against negative ESR2 findings. Although ER-> and ER-A are similar in structure and function, mechanistic differences between the two receptor subtypes may augment or minimize the effects of polymorphisms on cognition and mood. These differences include the binding and transcription efficacy for nonsteroidal ligands, 116 the levels of circulating 17A-estradiol needed to activate a particular promoter, 117 and cofactors that help to initiate transcription. 118 Although ESR2 is highly polymorphic, there may be fewer functional polymorphisms on the ESR2 versus ESR1 gene. To date, one functional ESR2 polymorphism has been identified in an African American population that influences estrogen binding affinity. 119 Future molecular and genetic association studies with the ESR2 gene will help to elucidate these possibilities. Finally, no studies have investigated mental health outcomes in relation to GPR30 polymorphisms, although GPR30 is found in the cortex, hippocampus, and locus coeruleus of rodent brain.
Lastly, there is a need for studies focusing on the clinical significance of ESR1 polymorphisms in relation to exogenous and endogenous estrogen levels. Bone mineral density has been shown to be more dependent on estradiol levels in men with the X and P alleles compared with men with the xx or pp genotypes. 120 In addition, women with the XX or PP genotypes show an augmented response of high-density lipoprotein cholesterol or serum sex hormoneYbinding globulin levels to hormone therapy. 35 These findings raise the possibility that the ESR1 genotype might modulate the relationship between endogenous or exogenous estrogen and mental health outcomes. In this way, genetic studies can provide additional insights into interindividual and intra-individual differences in the extent to which cognition and mood change with menopause and hormone therapy.
CONCLUSIONS
There seems to be strong evidence for a relationship between genetic variants on the ESR1 gene and cognitive outcomes. The relationships between ESR1 and cognitive impairment tend to be specific to or driven by women and restricted to risk for AD rather than other dementia causes. Case-control studies suggest that the X and P alleles of the Xbal and PvuII polymorphisms confer risk, whereas cohort studies suggest that the x and p alleles confer risk. Part of this discrepancy seems to be due to the greater prevalence of Asian cohorts among the case-control studies, as demonstrated in a meta-analysis of case-control studies that demonstrated that X and P are risk factors only in Asian cohorts. 66 Future studies that include haplotype, ethnicity-specific, and sex-stratified analyses may provide insights into the discrepant results. Most studies examined either AD or MMSE scores as primary outcomes; only two studies examined comprehensive neuropsychological test batteries. Episodic memory impairment has been shown in numerous studies to be the earliest and strongest neurocognitive predictor of AD. In the one study that examined ESR1 polymorphisms in relation to episodic memory performance, the x and p alleles were uniquely associated with an increased risk of episodic memory impairment in nondemented postmenopausal women. Future studies are needed to evaluate whether ESR1 polymorphisms are reliably associated with a lower level of memory performance in nondemented individuals.
Fewer studies have examined ESR1 variants in relation to mood outcomes, and these studies offer preliminary evidence for a relationship between ESR1 variants and risk for certain mood disorders including anxiety, depression, childhoodonset mood disorder, and premenstrual dysphoric disorder. Future studies are needed to explicitly evaluate whether ESR1 variants may help to explain the significant individual differences in the extent to which mood and cognition change as a function of reproductive stage, menstrual phase, postpartum, and hormone therapy use.
